Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
86
Recruiting, any sponsor type, condition "immune thrombocytopenia"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed218
86 trials
Showing 1 to 25, recently updated first.
- A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Newly Diagnosed Previously Untreated Primary Immune Thrombocytopenia (ITP)Pivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07700238 · 126 participants (planned) · Start Oct 15, 2026 · Primary completion Sep 14, 2029
Drug: Romiplostim; Predniso(lo)ne · For: Primary Immune Thrombocytopenia
Sites: Long Beach, California; Peoria, Illinois; Durham, North Carolina · 21 sites in all
The General Hospital of Western Theater CommandAcademic, hospital or other
NCT07622329 · 4 participants (planned) · Start Jun 18, 2026 · Primary completion Sep 2, 2026
Drug: JCXH-213 · For: Thrombocytopenic Purpura, Immune
Sites: Chengdu, China
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07421167 · 164 participants (planned) · Start Aug 4, 2026 · Primary completion Jan 18, 2029
Drug: ianalumab; thrombopoietin receptor agonist (TPO-RA) · For: Primary Immune Thrombocytopenia (ITP); Primary Evans Syndrome (ES)
Sites: Chandler, Arizona; Fayetteville, Arkansas; Torrance, California · 24 sites in all
- A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)Pivotal-lookingRecruiting
argenxargenx (ARGX)
NCT07194850 · 24 participants (planned) · Start Oct 20, 2025 · Primary completion Oct 2028
Drug: Efgartigimod IV · For: Immune Thrombocytopenia (ITP); ITP - Immune Thrombocytopenia; ITP and 4 more
Sites: Bordeaux, France; La Tronche, France; Vandœuvre-lès-Nancy, France · 28 sites in all
- Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUSPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05795140 · 65 participants (planned) · Start May 8, 2024 · Primary completion Jul 16, 2032
Drug: Iptcaopan 200 mg · For: Atypical Hemolytic Uremic Syndrome
Sites: São Paulo, Brazil; Rio de Janeiro, Brazil; Beijing, China · 10 sites in all
Shanghai Cell Therapy Group Co.,LtdIndustry
NCT07174843 · 20 participants (planned) · Start Sep 9, 2025 · Primary completion Aug 2027
Drug: CD19/CD22/BCMA CAR-T cells(BZE2204) · For: Idiopathic Inflammatory Myopathies(IIM); Immune Thrombocytopenia(ITP); Systemic Lupus Erythematosus(SLE)
Sites: Shanghai, China
TargED Biopharmaceuticals B.V.Industry
NCT07459114 · 70 participants (planned) · Start Oct 25, 2026 · Primary completion May 31, 2028
Drug: TGD001 · For: Thrombotic Microangiopathies; ITP Immune-Mediated Thrombocytopenia
Sites: Valencia, Spain
- Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line TreatmentPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07007962 · 60 participants (planned) · Start Oct 24, 2025 · Primary completion Nov 5, 2027
Drug: rilzabrutinib · For: Immune Thrombocytopenia
Sites: Clovis, California; Los Angeles, California; Torrance, California · 54 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT06721013 · 68 participants (planned) · Start Jul 30, 2025 · Primary completion Feb 2028
Drug: Pirtobrutinib; Placebo · For: Immune Thrombocytopenia (ITP)
Sites: Los Angeles, California; Palo Alto, California; Washington D.C., District of Columbia · 43 sites in all
- A Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06722235 · 171 participants (planned) · Start Feb 27, 2025 · Primary completion Mar 16, 2028
Drug: Mezagitamab; Placebo · For: Immune Thrombocytopenic Purpura (ITP)
Sites: Hot Springs, Arkansas; Los Angeles, California; San Diego, California · 124 sites in all
Incyte CorporationIncyte (INCY)
NCT07104565 · 56 participants (planned) · Start Dec 29, 2025 · Primary completion Sep 23, 2027
Drug: INCA000585 · For: Immune Thrombocytopenia
Sites: Glendale, Arizona; Los Angeles, California; Lone Tree, Colorado · 39 sites in all
- A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06948318 · 150 participants (planned) · Start Aug 14, 2025 · Primary completion Jul 29, 2029
Drug: Mezagitamab · For: Immune Thrombocytopenic Purpura (ITP)
Sites: Hot Springs, Arkansas; Los Angeles, California; San Diego, California · 118 sites in all
Mitchell CairoAcademic, hospital or other
NCT04099966 · 20 participants (planned) · Start Apr 1, 2021 · Primary completion Dec 31, 2026
Drug: alpha beta depletion · For: Acute Leukemia; Severe Aplastic Anemia; Non-hodgkin Lymphoma and 6 more
Sites: Valhalla, New York
- A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)Pivotal-lookingRecruiting
Kedrion S.p.A.Industry
NCT07059000 · 40 participants (planned) · Start Aug 13, 2025 · Primary completion Dec 2026
Drug: Kedrion IVIG 10% · For: Chronic Primary Immune Thrombocytopenia (ITP)
Sites: Los Angeles, California; Shirley, New York; Greenville, North Carolina · 28 sites in all
CRISPR Therapeutics AGIndustry
NCT07549698 · 60 participants (planned) · Start Jul 17, 2026 · Primary completion Dec 2033
Drug: CTX112 · For: Warm Autoimmune Hemolytic Anemia (WAIHA); ITP - Immune Thrombocytopenia; Warm Autoimmune Hemolytic Anemia and 1 more
Sites: Boston, Massachusetts; Rochester, Minnesota; Omaha, Nebraska · 12 sites in all
- Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune ThrombocytopeniaRecruiting
Nuvig Therapeutics, Inc.Industry
NCT07095127 · 30 participants (planned) · Start Sep 30, 2025 · Primary completion Jun 30, 2027
Drug: NVG-2089 · For: Immune Thrombocytopenia (ITP)
Sites: Washington D.C., District of Columbia; Boston, Massachusetts; Greenville, North Carolina
Hangzhou Sumgen Biotech Co., Ltd.Industry
NCT07710248 · 60 participants (planned) · Start Jun 11, 2026 · Primary completion May 17, 2027
Drug: low dose group; high dose group and 1 more · For: Primary Immune Thrombocytopenia
Sites: Fuzhou, China; Guangzhou, China; Liuzhou, China · 22 sites in all
- OM336 in Autoimmune CytopeniasRecruiting
Lakefront Biotherapeutics West LLCIndustry
NCT07083960 · 32 participants (planned) · Start Aug 1, 2025 · Primary completion Dec 2026
Drug: OM336 · For: AIHA - Warm Autoimmune Hemolytic Anemia; AIHA - Cold Autoimmune Hemolytic Anemia; ITP - Immune Thrombocytopenia
Sites: Duarte, California; Washington D.C., District of Columbia; Ann Arbor, Michigan · 7 sites in all
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07788456 · 38 participants (planned) · Start Jun 22, 2026 · Primary completion May 30, 2027
Drug: standard-dose methylprednisolone/prednisone.; thrombopoietin receptor agonist(TPO-RA), including but not limited to hetrombopag or eltrombopag. and 2 more · For: ITP - Immune Thrombocytopenia
Sites: Tianjin, China
Jiangsu BioJeTay Biotechnology Co., Ltd.Industry
NCT06929299 · 56 participants (planned) · Start May 12, 2025 · Primary completion Sep 2026
Drug: STSA-1301 subcutaneous injection; Placebo · For: Primary Immune Thrombocytopenia (ITP)
Sites: Bengbu, China; Beijing, China; Tangshan, China · 7 sites in all
Chugai PharmaceuticalIndustry
NCT06371417 · 144 participants (planned) · Start Aug 19, 2024 · Primary completion Mar 31, 2027
Drug: RAY121 · For: Antiphospholipid Syndrome (APS); Bullous Pemphigoid (BP); Behçet's Syndrome (BS) and 3 more
Sites: Orange, California; Baltimore, Maryland; Lake Success, New York · 77 sites in all
- Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune ThrombocytopeniaPivotal-lookingRecruiting
Chinese SLE Treatment And Research GroupAcademic, hospital or other
NCT07657793 · 164 participants (planned) · Start Jun 7, 2026 · Primary completion Sep 30, 2027
Drug: Sirolimus; Placebo · For: Systemic Lupus Erythematosus; Immune Thrombocytopenia
Sites: Beijing, China
University Hospital, BordeauxAcademic, hospital or other
NCT04800458 · 225 participants (planned) · Start May 19, 2021 · Primary completion May 2028
Drug: Blood samples · For: Thrombocytopenia; Immune Thrombocytopenia; Myelodysplasia
Sites: Pessac, France
Shanghai IASO Biotechnology Co., LtdIndustry
NCT06534021 · 16 participants (planned) · Start Aug 8, 2024 · Primary completion Oct 9, 2027
Drug: IASO-782 injection; placebo · For: Autoimmune Thrombocytopenia; Warm Autoimmune Haemolytic Anaemia
Sites: Wuhan, China; Tianjin, China
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
NCT07612319 · 60 participants (planned) · Start Mar 15, 2026 · Primary completion Sep 2027
Drug: Romiplostim · For: Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Sites: Suzhou, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.